Breaks Categories: Stock Spotlights

FridayApr 01, 2022 3:39 pm

BioMedNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Technologies Stand Distinct

Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up to five days. Besides causing discomfort upon insertion, users report trauma and bruising in addition to changes to the skin surface. In contrast, Nemaura Medical’s sugarBEAT(R) and proBEAT(TM) continuous glucose monitors (“CGMs”) sit on the surface of the skin, are easy to apply, and can…

Continue Reading

TuesdayMar 29, 2022 2:30 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, partnering to advance research and more. The company has partnered with Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University (“JHU”), to lead its planned placebo-controlled study evaluating the science and efficacy of MYCO-001, its lead psilocybin-based drug…

Continue Reading

FridayMar 25, 2022 2:19 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Committed to Execute More Programs to Grow Market Reach and Product Portfolio

InMed Pharmaceuticals (NASDAQ: INM) President and CEO Eric A. Adams recently hosted a conference call and webcast in which he emphasized the company’s successful product diversification and strategic acquisition achievements. He expressed his optimism at the company’s expansion into the health and wellness sector as an ingredient supplier and the integration of BayMedica’s operations and team into its ongoing activities. A recent article reads: “While noting how recent product launches have allowed the company to top its revenue estimates, Mr. Adams was also keen to point out its ongoing commitment to launch even more products in the coming months. He…

Continue Reading

TuesdayMar 22, 2022 2:53 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Valuable AI-Powered Insights to Diabetes Market

Nemaura Medical (NASDAQ: NMRD), a medical technology company developing and commercializing non-invasive wearable diagnostic devices, is positioned to offer innovative solutions to a rapidly growing market. According to a recent report released by the International Diabetes Federation (“IDF”), diabetes is “spiraling out of control.” According to the report, 537 million adults live with diabetes, a number projected to rise to 643 million by 2030 and 783 million by 2045. In addition to impacting the health and wellbeing of patients, employers and insurers are burdened with diabetes-related expenses, currently estimated at over $966 billion – a 316% increase over the last…

Continue Reading

FridayMar 18, 2022 2:02 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Commercialization Phase of Its Corporate Development, Recognizes First-Ever Revenues

Nemaura Medical (NASDAQ: NMRD) recently announced its Q3 FY 2022 results for the three months ended Dec. 31, 2021. The company reported revenues of $183,628 due to the initial shipments made over the past quarter of sugarBEAT(R) CGM devices to MySugarWatch, the company’s U.K. licensee. The order marked the inaugural revenues in Nemaura Medical’s history, with the company rapidly moving toward monetizing its recent product launches. “The December quarter marked a milestone for Nemaura, as we officially entered the commercialization phase of our corporate development and recognized revenues for the first time in our history,” a recent article quotes Nemaura…

Continue Reading

ThursdayMar 17, 2022 3:06 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Playing Pivotal Role in Renaissance of Psychedelics

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is among organizations, working alongside researchers at the center of the veritable renaissance of psychedelics. “Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first- and second-generation novel compounds for the treatment of mental health and addiction and sequentially collaborating with academics to undertake vital clinical research on them. So far, Mydecine has partnered with Johns Hopkins University to launch a clinical trial utilizing psilocybin for smoking cessation. Led…

Continue Reading

ThursdayMar 17, 2022 2:45 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier, is CNS Pharmaceuticals’ lead drug candidate. “The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma…

Continue Reading

WednesdayMar 16, 2022 2:26 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis and the proprietary IntegraSyn(TM) manufacturing models,” a recent article explains. “Together,…

Continue Reading

FridayMar 11, 2022 3:11 pm

BioMedNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Revolutionary sugarBEAT(R) CGM Device Met with Early Success

Nemaura Medical (NASDAQ: NMRD), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices also simultaneously promote routine glucose testing in a bid to control blood glucose levels more effectively. Nemaura offers two flagship constant glucose monitoring (“CGM”) products: the sugarBEAT(R), a non-invasive wearable diagnostic device, and MiBoKo, an application that supports personalized lifestyle coaching programs. A recent article reads: “The company’s revolutionary sugarBEAT(R) CGM device seeks to provide users with non-invasive glucose monitoring; as described by the company,…

Continue Reading

ThursdayMar 10, 2022 11:28 am

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health Canada had included the dealer’s license, under which the company operates, as a supplier for the Special Access Program (“SAP”). “SAP allows healthcare providers to seek specific drugs normally unavailable for sale in Canada for patients with serious or life-threatening conditions who are not responding…

Continue Reading